{"id":"NCT00654992","sponsor":"Seoul National University Bundang Hospital","briefTitle":"Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery","officialTitle":"Prevention of Acute Kidney Injury (AKI) by Erythropoietin (EPO) in Patients Undergoing Coronary Artery Bypass Grafting (CABG) Surgery - A Prospective Placebo-Controlled Randomized Trial","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-09","primaryCompletion":"2008-02","completion":"2009-02","firstPosted":"2008-04-09","resultsPosted":"2009-06-16","lastUpdate":"2009-06-16"},"enrollment":71,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Kidney Failure, Acute"],"interventions":[{"type":"DRUG","name":"Erythropoietin-Beta","otherNames":["recormon"]},{"type":"DRUG","name":"Normal Saline","otherNames":["0.9% saline"]}],"arms":[{"label":"EPO group","type":"ACTIVE_COMPARATOR"},{"label":"Placebo group","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether erythropoietin is effective in preventing acute kidney dysfunction after coronary artery bypass grafting surgery.","primaryOutcome":{"measure":"Number of Participants Who Had AKI (Acute Kidney Injury)","timeFrame":"at any time within the first 5 days after surgery","effectByArm":[{"arm":"Erythropoietin (EPO) Group","deltaMin":3,"sd":null},{"arm":"Placebo Group","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":1,"countries":["South Korea"]},"refs":{"pmids":["39301879"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}